Andrew Blauvelt

36.8k total citations · 23 hit papers
489 papers, 21.9k citations indexed

About

Andrew Blauvelt is a scholar working on Immunology, Dermatology and Physiology. According to data from OpenAlex, Andrew Blauvelt has authored 489 papers receiving a total of 21.9k indexed citations (citations by other indexed papers that have themselves been cited), including 331 papers in Immunology, 224 papers in Dermatology and 95 papers in Physiology. Recurrent topics in Andrew Blauvelt's work include Psoriasis: Treatment and Pathogenesis (260 papers), Dermatology and Skin Diseases (207 papers) and Asthma and respiratory diseases (94 papers). Andrew Blauvelt is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (260 papers), Dermatology and Skin Diseases (207 papers) and Asthma and respiratory diseases (94 papers). Andrew Blauvelt collaborates with scholars based in United States, Canada and Germany. Andrew Blauvelt's co-authors include Kim Papp, Kristian Reich, Andrea Chiricozzi, Mark Lebwohl, Diamant Thaçi, Stephen E. Kurtz, Alexa B. Kimball, Richard G. Langley, C.E.M. Griffiths and Shinji Kagami and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Andrew Blauvelt

439 papers receiving 21.4k citations

Hit Papers

Phase 3 Trials of Ixekizumab in ... 2000 2026 2008 2017 2016 2017 2018 2000 2010 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    2016 650 citations Kenneth B. Gordon, Andrew Blauvelt et al. profile →
  2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
    2017 637 citations Andrew Blauvelt, Kim Papp et al. Journal of the American Academy of Dermatology profile →
  3. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
    2018 539 citations Andrew Blauvelt et al. profile →
  4. Human skin Langerhans cells are targets of dengue virus infection
    2000 536 citations Andrew Blauvelt et al. profile →
  5. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice
    2010 508 citations Andrew Blauvelt, Robert L. Modlin et al. Journal of Clinical Investigation profile →
  6. Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
    2009 503 citations Andrew Blauvelt et al. Journal of Investigative Dermatology profile →
  7. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
    2018 452 citations Kenneth B. Gordon, Bruce Strober et al. profile →
  8. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
    2015 429 citations Diamant Thaçi, Andrew Blauvelt et al. Journal of the American Academy of Dermatology profile →
  9. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
    2017 413 citations Kristian Reich, Kim Papp et al. profile →
  10. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    2017 392 citations Kim Papp, Andrew Blauvelt et al. profile →
  11. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
    2016 376 citations Kim Papp, Kristian Reich et al. British Journal of Dermatology profile →
  12. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
    2021 350 citations Emma Guttman‐Yassky, Eric L. Simpson et al. profile →
  13. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
    2021 305 citations Andrew Blauvelt, Eric L. Simpson et al. profile →
  14. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
    2020 248 citations Emma Guttman‐Yassky, Andrew Blauvelt et al. profile →
  15. Bimekizumab versus Secukinumab in Plaque Psoriasis
    2021 230 citations Kristian Reich, Richard B. Warren et al. profile →
  16. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
    2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →
  17. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
    2021 170 citations Kenneth B. Gordon, Peter Foley et al. profile →
  18. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
    2021 169 citations Kristian Reich, Kim Papp et al. profile →
  19. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    2023 162 citations Jonathan I. Silverberg, Emma Guttman‐Yassky et al. profile →
  20. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
    2022 134 citations Kristian Reich, Jacob P. Thyssen et al. profile →
  21. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
    2022 122 citations Eric L. Simpson, Kim Papp et al. profile →
  22. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis
    2023 80 citations Amy S. Paller, Andrew Blauvelt et al. profile →
  23. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
    2023 72 citations Andrew Blauvelt, Jacob P. Thyssen et al. British Journal of Dermatology profile →

Peers

Andrew Blauvelt
Comparison fields: 5 of 163
  • Immunology 14.8k
  • Dermatology 9.6k
  • Physiology 3.5k
  • Rheumatology 3.1k
  • Oncology 2.4k
Replace Georg Stingl with:
Georg Stingl Austria
Thomas S. Kupper United States
Gerold Schuler Germany
Amy S. Paller United States
Francesco Annunziato Italy
Hergen Spits Netherlands
Mark H. Kaplan United States
Neal S. Young United States
Louis J. Picker United States
Olivier Hermine France
Georg Stingl Austria View profile →
Citations per field, relative to Andrew Blauvelt
Andrew Blauvelt · 1×
Citations per year, relative to Andrew Blauvelt
Andrew Blauvelt · 1×

Countries citing papers authored by Andrew Blauvelt

Since Specialization
Citations

This map shows the geographic impact of Andrew Blauvelt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Blauvelt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Blauvelt more than expected).

Fields of papers citing papers by Andrew Blauvelt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Blauvelt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Blauvelt. The network helps show where Andrew Blauvelt may publish in the future.

Co-authorship network of co-authors of Andrew Blauvelt

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Blauvelt. A scholar is included among the top collaborators of Andrew Blauvelt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Blauvelt. Andrew Blauvelt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis
2025 ·SKIN The Journal of Cutaneous Medicine ·Andrew Blauvelt, (unknown), (unknown), James M. Krueger, (unknown), Jóhann E. Guðjónsson, (unknown), Joana Gonçalves, Mark Lebwohl
0
2
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events
2025 ·Dermatology and Therapy ·Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, Carlo Salvarani, (unknown), Natalia Bello, (unknown), (unknown), (unknown), Marcus Ngantcha, Proton Rahman, Kim Papp, Joseph F. Merola, Alice B. Gottlieb, Andrew Blauvelt
2
3
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies
2024 ·American Journal of Clinical Dermatology ·Lawrence F. Eichenfield, Eric L. Simpson, Kim Papp, Jacek C. Szepietowski, Andrew Blauvelt, Leon Kircik, Jonathan I. Silverberg, Elaine C. Siegfried, Michael E. Kuligowski, May E. Venturanza, Howard Kallender, Haobo Ren, Amy S. Paller
8
4
52741 Efficacy of Abrocitinib Versus Dupilumab on Dermatitis in the Head-and-Neck Region of Patients With Moderate-To-Severe Atopic Dermatitis: A Post Hoc Analysis of the Phase 3 JADE DARE Study
2024 ·Journal of the American Academy of Dermatology ·April W. Armstrong, Melinda Gooderham, Kilian Eyerich, Kristian Reich, Andrew Blauvelt, Hwanhee Hong, Roger Edwards, (unknown), (unknown), (unknown), Claire Feeney
0
5
Efficacy of Deucravacitinib in Moderate to Severe Scalp Psoriasis: Analysis of Complete Clearance of Scalp Disease and Symptoms
2024 ·SKIN The Journal of Cutaneous Medicine ·Linda Stein Gold, Andrew Blauvelt, Leon Kircik, Andrew Napoli, (unknown), (unknown), (unknown), Jerry Bagel, Mark Lebwohl
1
6
Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy
2024 ·SHILAP Revista de lepidopterología ·Andrew Blauvelt, Richard G. Langley, Patrick Branigan, Xuejun Liu, Yanqing Chen, (unknown), Keying Ma, (unknown), Kim Campbell, Ernesto J. Muñoz‐Elías, Kim Papp
3
7
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study
2023 ·Journal of Dermatological Science ·Andrew Blauvelt, David M. Pariser, Stephen K. Tyring, Jerry Bagel, Andrew Alexis, Jennifer Soung, April W. Armstrong, Elisa Muscianisi, Farid Kianifard, Jennifer Steadman, (unknown), Sandra Garcet, James G. Krueger
11
8
Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
2023 ·SKIN The Journal of Cutaneous Medicine ·Mark Lebwohl, Richard B. Warren, Howard Sofen, (unknown), C. Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, (unknown), Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt
3
9
Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest
2023 ·SKIN The Journal of Cutaneous Medicine ·Kristian Reich, Eric L. Simpson, Richard G. Langley, Richard B. Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, (unknown), Andrew Blauvelt
1
10
LB1703 High induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: Interim results from the phase 2 KNOCKOUT study
2023 ·Journal of Investigative Dermatology ·Andrew Blauvelt, Jóhann E. Guðjónsson, Robert Matheson, Rong Liu, Ling Shi, (unknown), (unknown)
3
11
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials breakdown →
2023 ·British Journal of Dermatology ·Andrew Blauvelt, Jacob P. Thyssen, Emma Guttman‐Yassky, Thomas Bieber, E. Serra‐Baldrich, Eric L. Simpson, David Rosmarin, Hany Elmaraghy, (unknown), Chitra R Natalie, Zhuqing Liu, Chenjia Xu, Evangeline Pierce, (unknown), Esther García Gil, Jonathan I. Silverberg
72
12
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
2023 ·American Journal of Clinical Dermatology ·Eric L. Simpson, Andrew Pink, Andrew Blauvelt, Melinda Gooderham, April W. Armstrong, Margitta Worm, Norito Katoh, Ketty Peris, L. Puig, S. Barbarot, (unknown), Louise Abildgaard Steffensen, (unknown), Andreas Wollenberg
15
13
43757 Improvement in pigmentation changes by Fitzpatrick skin type in actinic keratosis patients treated with tirbanibulin ointment 1%: pooled data from two Phase III studies
2023 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt, Edward Lain, (unknown), (unknown), (unknown), Laura Padullés, F Hernández, (unknown)
0
14
44102 Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments
2023 ·Journal of the American Academy of Dermatology ·Jeffrey Crowley, Chih-ho Hong, Melinda Gooderham, Georgios Kokolakis, (unknown), Simone Rubant, Tianyu Zhan, Andrew Blauvelt
1
15
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up
2023 ·Journal of the American Academy of Dermatology ·Kim Papp, Andrew Blauvelt, L. Puig, Mamitaro Ohtsuki, Stefan Beissert, Melinda Gooderham, (unknown), Jie Liu, Tianshuang Wu, (unknown), (unknown), Ramon Espaillat, (unknown), Ahmed M. Soliman, Yinuo Pang, Michael M. Chen, Mark Lebwohl
30
16
Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance
2022 ·Journal of the European Academy of Dermatology and Venereology ·Kristian Reich, Kenneth B. Gordon, Bruce Strober, Richard G. Langley, Megan Miller, Ya‐Wen Yang, Yaung‐Kaung Shen, Yin You, Yaowei Zhu, Peter Foley, Andrew Blauvelt
20
17
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
2022 ·Dermatology and Therapy ·Andrew Blauvelt, Melinda Gooderham, Neal Bhatia, Richard G. Langley, (unknown), (unknown), Azra Kurbasic, April W. Armstrong, Jonathan I. Silverberg
6
18
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
2018 ·British Journal of Dermatology ·Caitriona Ryan, Alan Menter, Lyn Guenther, Andrew Blauvelt, Robert Bissonnette, K.A.P. Meeuwis, John Sullivan, Jennifer Clay Cather, Gil Yosipovitch, Alice B. Gottlieb, Joseph F. Merola, Kristina Callis Duffin, Scott Fretzin, Olawale Osuntokun, Russel Burge, April N. Naegeli, Fan Emily Yang, Chen‐Yen Lin, (unknown), Alison Potts Bleakman, (unknown)
85
19
Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells
2004 ·Journal of Clinical Investigation ·Robert E. Hunger, Peter A. Sieling, María Teresa Ochoa, Makoto Sugaya, Anne E. Burdick, Thomas H. Rea, Patrick J. Brennan, John T. Belisle, Andrew Blauvelt, Steven A. Porcelli, Robert L. Modlin
217
20
Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells
2004 ·Journal of Clinical Investigation ·Robert E. Hunger, Peter A. Sieling, María Teresa Ochoa, Makoto Sugaya, Anne E. Burdick, Thomas H. Rea, Patrick J. Brennan, John T. Belisle, Andrew Blauvelt, Steven A. Porcelli, Robert L. Modlin
200

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Georg Stingl Breakdown of academic impact, for papers by Thomas S. Kupper Breakdown of academic impact, for papers by Gerold Schuler Breakdown of academic impact, for papers by Amy S. Paller Breakdown of academic impact, for papers by Francesco Annunziato Breakdown of academic impact, for papers by Hergen Spits Breakdown of academic impact, for papers by Mark H. Kaplan Breakdown of academic impact, for papers by Neal S. Young Breakdown of academic impact, for papers by Louis J. Picker Breakdown of academic impact, for papers by Olivier Hermine
Rankless by CCL
2026